News

Biospace || Paradigm4 Joins the Tetra Partner Network to Leverage Tetra Data into High-performing Analytical Computing Applications for Pharmaceutical Customers

TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.

whitepages icon x

Clinical Omics | Pushing the Proteomics envelope

More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)

whitepages icon x

Paradigm4 Launches REVEAL: Proteomics to Transform the Search for Protein Isoform Biomarkers

BOSTON — Paradigm4 has today unveiled REVEAL™: Proteomics, the newest use case specific app powered by the Paradigm4 FLASH™ high-performance bioinformatics platform. REVEAL: Proteomics unlocks the power of advanced mass spec proteomics by simplifying cross sample and cross study searching for protein isoforms as potential biomarkers for drug response or

whitepages icon x

World Pharma Today || Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.